In this study, we illustrated that upregulated MUC2 expression is connected with aggressive clinicopathological features, and MUC2 can independently act as an unfavorable prognostic indicator and a druggable target for rectal cancer patients receiving CCRT. This evidence concerns the gene MUC2 and rectal cancer.